Head-To-Head Survey: Seres Therapeutics (MCRB) versus Its Competitors

Seres Therapeutics (NASDAQ:MCRB) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Seres Therapeutics to related companies based on the strength of its profitability, risk, dividends, earnings, valuation, analyst recommendations and institutional ownership.

Volatility & Risk

Seres Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Seres Therapeutics’ rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Seres Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1	1	2	0	2.25
Seres Therapeutics Competitors	9869	15283	45611	1598	2.54

Seres Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 1,080.56%. As a group, “Biotechnology” companies have a potential upside of 123.04%. Given Seres Therapeutics’ higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than its rivals.

Institutional and Insider Ownership

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Seres Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-2,209.55%	-194.42%	-58.15%
Seres Therapeutics Competitors	-12,323.33%	-195.38%	-30.39%

Earnings and Valuation

This table compares Seres Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seres Therapeutics	$790,000.00	$5.70 million	-0.29
Seres Therapeutics Competitors	$756.66 million	$13.58 million	-19.01

Seres Therapeutics’ rivals have higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Seres Therapeutics rivals beat Seres Therapeutics on 7 of the 13 factors compared.

About Seres Therapeutics

Seres Therapeutics, Inc. is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption. Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.